Seattle biotech scores $67.5M to treat migraines and Parkinson’s with drugs delivered deep into the nasal cavity by James Thorne on December 6, 2018December 6, 2018 at 10:43 am Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central nervous system disorders, such as migraines and Parkinson’s. This is… Read More